ADMA Biologics Inc $ADMA Position Boosted by Jump Financial LLC

Key Points

• Jump Financial LLC significantly increased its stake in ADMA Biologics, raising it by 1,420.0% during the first quarter, acquiring an additional 333,752 shares and owning approximately 0.15% of the company at the end of that quarter.
• Multiple institutional investors, including SVB Wealth LLC and Price T Rowe Associates Inc. MD, expanded their positions in ADMA Biologics, with institutional ownership now at 75.68%.
• Brokerage firms have mixed ratings on ADMA Biologics, with Raymond James Financial upgrading their target price to $32.00, while Wall Street Zen downgraded their rating to "sell".

Jump Financial LLC boosted its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 1,420.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 357,256 shares of the biotechnology company's stock after acquiring an additional 333,752 shares during the quarter. Jump Financial LLC owned 0.15% of ADMA Biologics worth $7,088,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ purchased a new position in ADMA Biologics in the first quarter valued at about $35,000. SVB Wealth LLC purchased a new position in ADMA Biologics in the first quarter valued at about $35,000. Smartleaf Asset Management LLC raised its position in ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 1,493 shares during the period. Tsfg LLC purchased a new position in ADMA Biologics in the first quarter valued at about $51,000. Finally, Brooklyn Investment Group raised its position in ADMA Biologics by 28,655.6% in the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock valued at $51,000 after purchasing an additional 2,579 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 455,621 shares of company stock worth $9,461,633 over the last quarter. 3.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ADMA has been the topic of several research reports. Raymond James Financial raised their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $27.67.

ADMA Biologics Stock Down 0.7%

NASDAQ ADMA traded down $0.12 on Friday, hitting $17.26. 2,527,726 shares of the stock traded hands, compared to its average volume of 3,388,413. The stock has a 50-day moving average of $17.76 and a 200 day moving average of $18.91. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a market capitalization of $4.12 billion, a P/E ratio of 20.07 and a beta of 0.38. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. During the same quarter in the prior year, the firm posted $0.13 earnings per share. ADMA Biologics's revenue for the quarter was up 13.8% compared to the same quarter last year. As a group, analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.